Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Prostate Cancer

  Free Subscription


1 Anticancer Res
2 BJU Int
3 BMC Urol
1 Br J Cancer
1 Cancer
1 Discov Oncol
2 Eur J Radiol
2 Eur Urol
2 Int J Cancer
4 Int J Urol
1 J Clin Oncol
1 J Natl Med Assoc
1 Nat Rev Urol
1 Oncol Rep
1 PLoS One
9 Prostate
1 Urol Int

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Anticancer Res

  1. YAMAMOTO T, Umezawa R, Shimada S, Takahashi N, et al
    The Impact of Pathological Grade Group 3 on Relapse-free Survival After Salvage Radiotherapy for Postoperative Prostate Cancer.
    Anticancer Res. 2023;43:5115-5125.
    PubMed         Abstract available

    BJU Int

  2. KAUFMANN B, Raess E, Schmid FA, Bieri U, et al
    Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial.
    BJU Int. 2023 Oct 27. doi: 10.1111/bju.16213.
    PubMed         Abstract available

  3. BAGGULEY D, Harewood L, McKenzie D, Ptasznik G, et al
    CONFIRM trial Protocol: The utility of PSMA PET/CT in active surveillance for prostate cancer.
    BJU Int. 2023 Oct 30. doi: 10.1111/bju.16214.
    PubMed         Abstract available

    BMC Urol

  4. GARIN O, Kowalski C, Zamora V, Roth R, et al
    Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry.
    BMC Urol. 2023;23:178.
    PubMed         Abstract available

  5. SEMBA R, Uchida K, Hirokawa Y, Shiraishi T, et al
    Short-term prognosis of low-risk prostate cancer patients is favorable despite the presence of pathological prognostic factors: a retrospective study.
    BMC Urol. 2023;23:174.
    PubMed         Abstract available

  6. WANG G, Wang X, Du H, Wang Y, et al
    Prediction model of gleason score upgrading after radical prostatectomy based on a bayesian network.
    BMC Urol. 2023;23:159.
    PubMed         Abstract available

    Br J Cancer

  7. FENG X, Zhang Y, Vaselkiv JB, Li R, et al
    Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.
    Br J Cancer. 2023 Oct 28. doi: 10.1038/s41416-023-02472.
    PubMed         Abstract available


    Targeting metabolic abnormality for advanced prostate cancer: The prodrug Platin-L effectively targets the metabolic abnormality needed to make this cancer sensitive to cisplatin.
    Cancer. 2023;129:3516.

    Discov Oncol

  9. BIAN Q, Li B, Zhang L, Sun Y, et al
    Molecular pathogenesis, mechanism and therapy of Cav1 in prostate cancer.
    Discov Oncol. 2023;14:196.
    PubMed         Abstract available

    Eur J Radiol

  10. SINGH S, Giganti F, Dickinson L, Rogers H, et al
    Prostate MR image quality of apparent diffusion coefficient maps versus fractional intracellular volume maps from VERDICT MRI using the PI-QUAL score and a dedicated Likert scale for artefacts.
    Eur J Radiol. 2023;168:111109.
    PubMed         Abstract available

  11. FLEMING H, Dias AB, Talbot N, Li X, et al
    Inter-reader variability and reproducibility of the PI-QUAL score in a multicentre setting.
    Eur J Radiol. 2023;168:111091.
    PubMed         Abstract available

    Eur Urol

  12. EAPEN RS, Buteau JP, Jackson P, Mitchell C, et al
    Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study.
    Eur Urol. 2023 Oct 25:S0302-2838(23)03087-7. doi: 10.1016/j.eururo.2023.
    PubMed         Abstract available

  13. DE VOS II, Remmers S, Hogenhout R, Roobol MJ, et al
    Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
    Eur Urol. 2023 Oct 31:S0302-2838(23)03207-4. doi: 10.1016/j.eururo.2023.
    PubMed         Abstract available

    Int J Cancer

  14. FREI K, Schecher S, Daher T, Horner N, et al
    Inhibition of the Cyclin K-CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
    Int J Cancer. 2023 Nov 2. doi: 10.1002/ijc.34778.
    PubMed         Abstract available

  15. NG HUNG SHIN B, Tan S, Rhee H, Chung E, et al
    Impact of the COVID-19 pandemic on delivery of prostate cancer care in Australia: An interrupted time series analysis.
    Int J Cancer. 2023 Nov 3. doi: 10.1002/ijc.34759.
    PubMed         Abstract available

    Int J Urol

  16. YUASA T
    Editorial Comment to Bone-modifying agents are protective for symptomatic skeletal events in radium-223 treatment.
    Int J Urol. 2023;30:1034-1035.

    Evaluation of sexual function after robot-assisted radical prostatectomy: A farewell to IIEF questionnaire.
    Int J Urol. 2023;30:959-967.
    PubMed         Abstract available

  18. BLAS L, Shiota M, Matsumoto T, Hori Y, et al
    Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
    Int J Urol. 2023;30:1029-1034.
    PubMed         Abstract available

  19. KOHADA Y, Hieda K, Miyamoto S, Tasaka R, et al
    Retrospective evaluation of the improvement in the urinary status-related quality of life after robot-assisted radical prostatectomy.
    Int J Urol. 2023;30:1020-1027.
    PubMed         Abstract available

    J Clin Oncol

  20. GONG J, Kim DM, De Hoedt AM, Bhowmick N, et al
    Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?
    J Clin Oncol. 2023 Oct 27:JCO2300949. doi: 10.1200/JCO.23.00949.
    PubMed         Abstract available

    J Natl Med Assoc

  21. MOUZANNAR A, Delgado J, Kwon D, Atluri VS, et al
    Racial disparity in the utilization of immunotherapy for advanced prostate cancer.
    J Natl Med Assoc. 2023 Oct 28:S0027-9684(23)00107.
    PubMed         Abstract available

    Nat Rev Urol

  22. MORI JO, Elhussin I, Brennen WN, Graham MK, et al
    Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer.
    Nat Rev Urol. 2023 Oct 31. doi: 10.1038/s41585-023-00827.
    PubMed         Abstract available

    Oncol Rep

  23. LEE DY, Lee S, Kim YS, Park S, et al
    Cyclosporin A inhibits prostate cancer growth through suppression of E2F8 transcription factor in a MELK?dependent manner.
    Oncol Rep. 2023;50:218.
    PubMed         Abstract available

    PLoS One

  24. JOHANSSON P, Joneus P, Langenskiold S
    Causal inferences and real-world evidence: A comparative effectiveness evaluation of abiraterone acetate against enzalutamide.
    PLoS One. 2023;18:e0293000.
    PubMed         Abstract available


  25. GOVINDAN S, Cheranda N, Riekhof F, Luo S, et al
    Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Prostate. 2023 Nov 1. doi: 10.1002/pros.24644.
    PubMed         Abstract available

  26. ALSAIDAN OA, Onobun E, Ye C, Lou L, et al
    Inhibition of N-myristoyltransferase activity promotes androgen receptor degradation in prostate cancer.
    Prostate. 2023 Oct 31. doi: 10.1002/pros.24645.
    PubMed         Abstract available

  27. DI H, Wen Y
    Vasectomy and risk of prostate cancer: A Mendelian randomization study and confounder analysis.
    Prostate. 2023 Oct 31. doi: 10.1002/pros.24646.
    PubMed         Abstract available

  28. FU W, Xu L, Chen Y, Zhang Z, et al
    Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear translocation and increasing ferritinophagy.
    Prostate. 2023 Oct 30. doi: 10.1002/pros.24642.
    PubMed         Abstract available

  29. MAHMOUD AM, Childs DS, Ahmed ME, Tuba Kendi A, et al
    Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis.
    Prostate. 2023 Oct 29. doi: 10.1002/pros.24643.
    PubMed         Abstract available

  30. ECHEVERRIA CE, Oyarzun VI, Lopez-Cortes A, Cancino J, et al
    Biological role of fructose in the male reproductive system: Potential implications for prostate cancer.
    Prostate. 2023 Oct 27. doi: 10.1002/pros.24631.
    PubMed         Abstract available

  31. ZENG J, Zhang Y, Xu R, Chen H, et al
    Nanomechanical-based classification of prostate tumor using atomic force microscopy.
    Prostate. 2023;83:1591-1601.
    PubMed         Abstract available

  32. BELUE MJ, Blake Z, Yilmaz EC, Lin Y, et al
    Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?
    Prostate. 2023;83:1519-1528.
    PubMed         Abstract available

  33. MIYAHIRA AK, Soule HR
    The 29th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2023 Nov 1:e24640. doi: 10.1002/pros.24640.
    PubMed         Abstract available

    Urol Int

  34. SHEN C, Zhang DL, Cheng XL, Zhang WC, et al
    Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures.
    Urol Int. 2023;107:841-847.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.